Edit Bardi

Edit Bardi

Auto-generated profile, based on publicly available information

Edit Bardi

St Anna Children’s Hospital, Department of Paediatrics and Adolescent Medicine , Vienna

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2015 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
EBEdit Bardi
Edit Bardi
JAJan Astermark
Jan Astermark

14 July 2004 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
EBEdit Bárdi
Edit Bárdi
AOAnna V. Oláh
Anna V. Oláh
KBKatalin Bartyik
Katalin Bartyik
EEEmőke Endreffy
Emőke Endreffy
CJCsaba Jenei
Csaba Jenei
CKCsongor Kiss
Csongor Kiss

1 September 2007 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
EBEdit Bárdi
Edit Bárdi
IBIldikó Bobok
Ildikó Bobok
AOAnna V. Oláh
Anna V. Oláh
JKJános Kappelmayer
János Kappelmayer
CKCsongor Kiss
Csongor Kiss

1 August 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
RKRebecca J. van Kalsbeek
Rebecca J. van Kalsbeek
HPHelena J.H. van der Pal
Helena J.H. van der Pal
LHLars Hjorth
Lars Hjorth
GMGisela Michel
Gisela Michel
RHRiccardo Haupt
Riccardo Haupt
JDJeroen Te Dorsthorst
Jeroen Te Dorsthorst

16 July 2004 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
CKCsongor Kiss
Csongor Kiss
EBEdit Bárdi
Edit Bárdi
IBIldikó Bobok
Ildikó Bobok
AOAnna V. Oláh
Anna V. Oláh
ÉOÉva Oláh
Éva Oláh
JKJános Kappelmayer
János Kappelmayer

1 July 2021 in The Lancet Haematology
Verified
Journal Article
Open access
AAAndishe Attarbaschi
Andishe Attarbaschi
EBEdit Bardi
Edit Bardi
SBShlomit Barzilai-Birenboim
Shlomit Barzilai-Birenboim
DBDeepa Bhojwani
Deepa Bhojwani
MHMelanie M Hagleitner
Melanie M Hagleitner
EZEster Zapotocka
Ester Zapotocka
5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritised severe toxicities are based on generic considerations of relevance to any other cancer diagnosis and age group.